Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?
Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards at least for B-cell lymphoma have undergone significant changes, thereby...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
09 June 2021
|
| In: |
Hematological oncology
Year: 2021, Volume: 39, Issue: S1, Pages: 100-103 |
| ISSN: | 1099-1069 |
| DOI: | 10.1002/hon.2845 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/hon.2845 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2845 
|
| Author Notes: | Peter Dreger |
| Summary: | Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards at least for B-cell lymphoma have undergone significant changes, thereby questioning the traditional role of alloHCT in these diseases. This paper attempts to describe the current place and the perspectives of alloHCT in the rapidly evolving treatment landscape of NHL. |
|---|---|
| Item Description: | Gesehen am 02.07.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1099-1069 |
| DOI: | 10.1002/hon.2845 |